WHEAT RIDGE, CO--(MARKET WIRE)--Jun 12, 2007 -- GeneThera, Inc. (OTC BB:GTHA.OB - News) announced today that it received a contract from the Intramural Research Program, National Institute on Aging, and National Institutes of Health (NIH) to genetically engineer monoclonal antibodies and make them "clinically usable." The antibodies are expected to be used for treatment of hypertension.
